Skip to content

Research on the Application of Esketamine in Opioid-Free General Anesthesia in Elderly Total Hip Arthroplasty

Research on the Application of Esketamine in Opioid-Free General Anesthesia in Elderly Total Hip Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095184
Enrollment
Unknown
Registered
2025-01-03
Start date
2025-01-03
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

femoral neck fracture

Interventions

Control group (Group C):Patients in group C were given intravenous injection of propofol 1-1.5 mg/kg, etomidate 0.15-0.2mg/kg, midazolam 0.04-0.05mg/kg, sufentanil 0.4-0.5µg/kg, and rocuronium 0.6-0.7
Experimental group (Group OF):Patients in group OF were given intravenous injection of propofol 1-1.5 mg/kg, etomidate 0.15-0.2mg/kg, midazolam 0.04-0.05mg/kg, esketamine 0.4-0.5mg/kg, and rocuronium

Sponsors

The First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who met the indications of total hip arthroplasty and were informed about the study and signed the informed consent form were selected; 2. Age 60-80 years old; 3. ASA grade ?-?; 4, can speak Mandarin, communication barrier; 5. There were no obvious abnormalities in heart, lung, liver and kidney function

Exclusion criteria

Exclusion criteria: 1. Refuse to participate in this research; 2. Complicated with important organ dysfunction; 3. Patients with severe hypertension and diabetes mellitus; 4. Those who are allergic to the test drugs; 5. Patients with severe bradycardia and conduction block; 6. Patients with chronic pain, mental illness, or history of alcohol or drug abuse who were unable to cooperate with the trial; 7. Long-term use of sedative or analgesic drugs; 8. Increased intracranial pressure or intraocular pressure;

Design outcomes

Primary

MeasureTime frame
Incidence of opioid-related adverse reactions within 24h after surgery;Incidence of opioid-related adverse reactions within 48h after surgery;

Secondary

MeasureTime frame
Incidence of perioperative bradycardia ;Incidence of perioperative hypotension;Perioperative heart rate;Perioperative blood pressure (SBP, DBP, MAP);Length of PACU stay;Time of tracheal extubation;VAS scores of pain at rest and during movement at 6h after surgery were recorded;VAS scores of pain at rest and during movement at 12h after surgery were recorded;VAS scores of pain at rest and during movement at 24h after surgery were recorded;VAS scores of pain at rest and during movement at 48h after surgery were recorded;The scores of QoR-15 scale at 24h after surgery were recorded;The scores of QoR-15 scale at 48h after surgery were recorded;The number of PCIA compressions within 24h after surgery was recorded;The number of PCIA compressions within 48h after surgery was recorded;The use of additional analgesics within 24h after surgery was recorded;The use of additional analgesics within 48h after surgery was recorded;Patient satisfaction with anesthesia 24h after surgery(including satisfaction and dissatisfaction);

Countries

China

Contacts

Public ContactLifeng Wang

The First Affiliated Hospital of Gannan Medical University

wwwanglifeng@126.com+86 135 7671 5202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026